Scripps Research Institute: Long-acting Injectable Malaria Drug Enters First-in-Human Study
January 24, 2025
January 24, 2025
LA JOLLA, California, Jan. 24 (TNSres) -- The Scripps Research Institute issued the following news:
* * *
Calibr-Skaggs' long-acting injectable (LAI) platform transforms oral malaria treatment atovaquone, aiming for protection from malaria for three months.
* * *
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, designed a long-acting preventative medicine for malaria (CBE161 . . .
* * *
Calibr-Skaggs' long-acting injectable (LAI) platform transforms oral malaria treatment atovaquone, aiming for protection from malaria for three months.
* * *
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, designed a long-acting preventative medicine for malaria (CBE161 . . .